Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RK015
- Development stage
- Preclinical
- Lead developer
- RevolKa
- Modality
- Recombinant Proteins and Enzymes
01
Overview
RK015 is an investigational protein-based drug candidate being developed by RevolKa, a biotechnology company focused on protein engineering. The candidate is discovered and optimized using RevolKa's proprietary technology platform, which integrates directed evolution with artificial intelligence to design proteins with enhanced therapeutic properties. As of current public disclosures, RK015 is in the early research and development stage (listed as 'Working' in the company pipeline). Specific details regarding its molecular target, mechanism of action, and primary disease indications have not been disclosed by the developer.
Beyond the preview
Go deeper on RK015.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RK015.